Acquired Company

Assertio Holdings, Inc. completed the acquisition of Spectrum Pharmaceuticals, Inc. on July 31, 2023.

Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future. Show more

Pharmaceutical Preparation Manufacturing

Manufacturing

Start AI Chat

Market Cap

0.00

52 Wk Range

$N/A - $N/A

Previous Close

$1.03

Open

$1.03

Volume

N/A

Day Range

$1.03 - $1.03

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

9.68%

Institutional Own.

22.70%

Qtr Updated

09/30/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ROLVEDON™ (ex ROLONTIS™) (eflapegrastim) Details Blood disorder, Genetic disorder, Achromatopsia	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Poziotinib Details Non-small cell lung carcinoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.